Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: gastrointestinal perforations or fistulae compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Overall survival · patients with extensive SCLC without previous treatment
1 finding from 1 review
Adverse effects · patients with extensive SCLC without previous treatment
1 finding from 1 review
Overall survival · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy may leads to lower progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effects: at least one serious adverse event · People with advanced non‐small cell lung cancer
It is very uncertain whether TG4010 added to chemotherapy changes participants with at least one serious adverse event compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Survival rates at 3 years · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy showed no clear difference in survival rates at 3 years compared with chemotherapy alone (low certainty).
1 finding from 1 review
Survival rates at 5 years · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean CD4% Increase During Chemo · Kaposi sarcoma in children with HIV‐1 infection
1 finding from 1 review
no estimate extracted
48 participants
Very low
All‐cause mortality · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes mortality compared with ART (very low certainty).
1 finding from 1 review
RR 0.72 [0.37, 1.43]
50 participants
Very low
Complete response · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete Response to Tx compared with ART (very low certainty).
1 finding from 1 review
RR 1.57 [0.22, 11.34]
89 participants
Very low
Complete response plus partial response Length of · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete/Partial Response to Tx compared with ART (very low certainty).
1 finding from 1 review
RR 5.75 [1.59, 20.73]
39 participants
Very low
Complete Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete Among Known Outcome compared with ART (very low certainty).
1 finding from 1 review
RR 0.84 [0.48, 1.48]
26 participants
Very low
Complete/Partial Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete/Partial Among Known Outcome compared with ART (very low certainty).
1 finding from 1 review
RR 1.13 [0.67, 1.89]
26 participants
Very low
Progression‐free survival · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with observation (moderate certainty).
3 findings from 1 review
RR 1.07 [0.91, 1.25]
4 studies · 541 participants
Moderate
RR 1.06 [0.97, 1.17]
3 studies · 761 participants
Moderate
RR 0.96 [0.65, 1.41]
2 studies · 219 participants
Moderate
Progression‐free survival · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with maintenance radiotherapy (low certainty).
3 findings from 1 review
RR 1.07 [0.75, 1.54]
1 study · 141 participants
Low
RR 0.86 [0.55, 1.37]
1 study · 141 participants
Low
RR 0.89 [0.51, 1.55]
1 study · 141 participants
Low
3‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 3‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
5‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 5‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review
10‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 10‐year OS compared with maintenance radiotherapy (low certainty).
1 finding from 1 review